← Back to Clinical Trials
Recruiting NCT07714330

NCT07714330 Effectiveness of Audio Cues to Achieve Positional Therapy in Patients With Positional Obstructive Sleep Apnea

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07714330
Status Recruiting
Phase
Sponsor SleepDev, Inc
Condition Obstructive Sleep Apnea (OSA)
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-06-25
Primary Completion 2026-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Investigational Positional Therapy Device

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-06-25 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patients with obstructive sleep apnea (OSA) often experience more frequent and severe breathing disturbances when sleeping in the supine (back-sleeping) position compared with non-supine positions. Positional therapy aims to reduce time spent sleeping in the supine position, but existing treatment options may be limited by comfort and effectiveness. This study evaluates the effectiveness and usability of WhisperPT, an investigational in-ear positional therapy device that delivers gentle audio cues during sleep to encourage participants to move from the supine to a non-supine sleeping position. The study will assess the device's ability to reduce the apnea-hypopnea index (AHI), decrease time spent sleeping supine, and evaluate participant comfort and ease of use.

Eligibility Criteria

Inclusion Criteria: * Diagnosing sleep study identified a significant positional component to their obstructive sleep apnea (OSA) diagnosis as measured by at least a 50% reduction in Apnea-Hypopnea Index (AHI) while sleeping non-supine compared to supine * Diagnosing sleep study included at least 40% of the night recorded in supine and at least 20% of the night in non-supine position * Have an overall AHI \> 10 (4% desaturation) * Diagnosing sleep study included a minimum of 5 hours total sleep time (TST) * Willing to abstain from use of any other treatments for sleep-disordered breathing beginning at least 3 days prior to at-home study testing and for the remaining duration of their study participation * Between ages 18-75 * Must be able to refrain from alcohol use during nights of at-home study testing * Speaks and reads English sufficiently to understand the study informed consent, study instructions, and study materials * Signs study-specific informed consent form Exclusion Criteria: -Active medical conditions that would prevent study participation as determined by the principal investigator, including: Inability to easily move from between back and side in both directions Inability to sleep in lateral or supine position due to injury or a medical condition OR inability to sleep in a non-elevated/ tilted bed * Requiring medications to sleep * Prior diagnosis of a significant other sleep disorder such as restless leg syndrome/periodic limb movement disorder, primary central sleep apnea, pronounced insomnia, parasomnias, central disorder of hypersomnolence, etc * An active ear infection OR an ear infection within the past month OR a history of \>3 ear infections per year * Unusual outer ear, including enlarged or extra small anatomy, that prevents device use * Significant hearing impairment or ear skin issues, including: Participants with cochlear implants or those who will be affected by small magnets in the ear * Suffering from tinnitus * BMI \>35 * Current use of any illegal drugs. * Currently pregnant or currently lactating * Current enrollment in a clinical study of any other unapproved investigational drug or device. * Inability or unwillingness to comply with the study requirements. * Any other condition or laboratory value that could, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the participant.

Contact & Investigator

Central Contact

Michael Swertfager

✉ mswertfager@sleepdev.com

📞 408-499-6884

Principal Investigator

Michael Swertfager

STUDY CHAIR

SleepDev, Inc

Frequently Asked Questions

Who can join the NCT07714330 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Obstructive Sleep Apnea (OSA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07714330 currently recruiting?

Yes, NCT07714330 is actively recruiting participants. Contact the research team at mswertfager@sleepdev.com for enrollment information.

Where is the NCT07714330 trial being conducted?

This trial is being conducted at Burlingame, United States.

Who is sponsoring the NCT07714330 clinical trial?

NCT07714330 is sponsored by SleepDev, Inc. The principal investigator is Michael Swertfager at SleepDev, Inc. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology